Acalabrutinib Monotherapy vs Investigator's Choice of Treatment in Patients With CL Leukaemia and Heart Failure

This will be a global Phase IV, open-label, randomised study to evaluate the safety and tolerability of acalabrutinib (monotherapy, 100 mg orally \[po\], twice daily \[bd\]) compared to investigator's choice of treatment, in patients with CLL (TN or R/R) and moderate to severe cardiac impairment. Patients with moderate to severe cardiac impairment will include those with moderate to severe cardiac conditions, who may have been excluded from previous acalabrutinib clinical trials and in whom the safety of acalabrutinib was not systematically assessed. The study is planned to take place in appr

Trial Details

NCT ID
NCT06651970
Phase
PHASE4
Sponsor
AstraZeneca
Status
RECRUITING
Cancer Type
Leukemia
Interventions
  • Acalabrutinib
  • Investigator's choice of treatment
Locations (sample)
  • Charlotte, North Carolina, United States|35.22709,-80.84313
  • Columbus, Ohio, United States|39.96118,-82.99879
  • Philadelphia, Pennsylvania, United States|39.95238,-75.16362
  • Brno, Czechia|49.19522,16.60796
  • Hradec Králové, Czechia|50.20923,15.83277

Key Eligibility Criteria

  • Men and women ≥ 18 years of age, at the time of signing the informed consent.
  • Eastern Cooperative Oncology Group performance status of 0 to 3
  • Meet at least one of the following cardiovascular inclusion criteria: - Left ventricular ejection fraction (LVEF) \< 50% as assessed by local ECHO …
  • Diagnosis of CLL

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Leukemia Trials on Trialify →